Kailera Therapeutics
KLRA
11.02
-0.56
-4.84%
Kailera Therapeutics
US · KLRA
#3073 by market cap
Listed 2026
11.02
-0.56
-4.84%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | -- | 49.23M |
| Research & development | -- | 109.11M |
| Operating profit | -- | -158.34M |
| Pretax profit | -- | -148.96M |
| Tax | -- | -- |
| Net profit | -- | -148.96M |
| Basic EPS | -- | -1 |
| Diluted EPS | -- | -1.26 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 11.13M | 13.12M | 14.66M | 13.79M | 20.31M | 21.67M |
| Research & development | 19.52M | 26.99M | 52.47M | 70.87M | 101.06M | 84.67M |
| Operating profit | -30.65M | -40.11M | -67.12M | -84.66M | -121.37M | -106.34M |
| Pretax profit | -28.95M | -39.62M | -62.40M | -78.87M | -111.31M | -95.67M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -28.95M | -39.62M | -62.40M | -78.87M | -111.31M | -95.67M |
| Basic EPS | 0 | 0 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.25 | -0.34 | -0.53 | -0.67 | -1.09 | -0.74 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 177.61M | 557.54M |
| Cash & ST investments | 175.18M | 546.06M |
| Inventory | -- | -- |
| Total assets | 178.45M | 692.29M |
| Total current liabilities | 6.91M | 46.41M |
| Short-term debt | 509.00K | 1.04M |
| Long-term debt | -- | -- |
| Total liabilities | 397,217,000.00 | 1,048,752,000.00 |
| Total equity | -218.77M | -356.46M |
| Retained earnings | -219.71M | -368.67M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | -- | -- | 557.54M | 530.32M | 929.17M | 919.76M |
| Cash & ST investments | -- | -- | 546.06M | 519.17M | 916.74M | 901.45M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | -- | -- | 692.29M | 624.76M | 1.21B | 1.08B |
| Total current liabilities | -- | -- | 46.41M | 54.84M | 83.65M | 42.12M |
| Short-term debt | -- | -- | 1.04M | 1.03M | 1.05M | 1.09M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | -- | -- | 1,048,752,000.00 | 1,056,844,000.00 | 92,952,000.00 | 51,062,000.00 |
| Total equity | -- | -- | -356.46M | -432.09M | 1.12B | 1.03B |
| Retained earnings | -- | -- | -368.67M | -447.53M | -558.84M | -654.51M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -- | -120.21M |
| Depreciation & amortization | -- | 310.00K |
| Free cash flow | -- | -122.30M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | -- | 161.03M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | -26.23M | -29.70M | -46.08M | -68.31M | -77.53M | -133.67M |
| Depreciation & amortization | 62.00K | 63.00K | 122.00K | 101.00K | 101.00K | 101.00K |
| Free cash flow | -26.23M | -30.14M | -47.73M | -68.31M | -77.53M | -133.67M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | -- | -- | -- | 0 |
| Ending cash balance | 102.13M | 98.68M | 161.03M | 112.59M | 131.06M | 107.30M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -- | -34.21 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 25.70 | 12.01 |
| Quick ratioi | 25.35 | 11.83 |
| Debt / assetsi | 0.29 | 1.55 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -26.12 | -33.77 |
| ROA %i | -- | -- | -34.21 | -33.59 | -24.12 | -32.18 |
| ROIC %i | -- | -- | -- | -- | -27.92 | -36.46 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | -- | 12.01 | 9.67 | 11.11 | 21.84 |
| Quick ratioi | -- | -- | 11.83 | 9.53 | 11.03 | 21.55 |
| Debt / assetsi | -- | -- | 1.55 | 1.68 | 0.84 | 0.92 |
| LT debt / equityi | -- | -- | -- | -- | 0.82 | 0.86 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Kailera Therapeutics discussion 0 comments